Drugs / torcetrapib
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 314 trials · 3 missed | ||||||
| Phase 3 | NCT00267254 | Jan → Aug 2006 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00267267 | Jan 2006 → Jan 2007 | hyperlipidemia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00267280 | Jan → Dec 2006 | hyperlipidemia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00134485 | Mar 2005 → Mar 2006 | familial hypercholesterolemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00139061 | Mar 2005 → May 2006 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00134511 | Mar → Nov 2005 | homozygous familial hypercholesterolemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00145431 | Mar 2005 → Dec 2006 | hyperlipoproteinemia type 3 | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00134498 | Feb 2005 → Nov 2006 | hypertriglyceridemia 2 | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00137462 | Nov 2004 → Sep 2006 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00134264 | Jul 2004 → Jun 2007 | coronary artery disorder, diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00138762 | Jul 2004 → Aug 2006 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00136981 | Dec 2003 → Nov 2006 | familial hypercholesterolemia | Pfizer | Completed | Missed primary |
| Phase 3 | NCT00134238 | Nov 2003 → Dec 2006 | hyperlipidemia, combined, 2 | Pfizer | Terminated | Missed primary |
| Phase 3 | NCT00134173 | Oct 2003 → Sep 2006 | coronary atherosclerosis, hyperlipidemia | Pfizer | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | torcetrapib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00267254 ↗ |
| Known as | CP-529,414 | “Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months” NCT00134485 ↗2“Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone” NCT00145431 ↗ “Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally” NCT00134498 ↗ |
| Action | Inhibit | “The cholesteryl ester transfer protein inhibitor torcetrapib failed to slow atherosclerosis progression and increased mortality.” PMID 19029466 ↗ Nov 2008 |
| Modality | Small molecule | — CHEMBL479527 ↗ |
| Route | Oral | “Fixed Combination Torcetrapib/Atorvastatin, Administered Orally” NCT00134264 ↗ |
| Target | CETP | “Torcetrapib, an inhibitor of cholesteryl ester transfer protein” PMID 19029469 ↗ Nov 2008 |